Castle Biosciences (CSTL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, at the San Luis Resort, Galveston, Texas, with voting available online, by mail, or in person.
Record date for voting eligibility set as April 1, 2026.
Voting matters and shareholder proposals
Election of three Class I director nominees to serve until the 2029 annual meeting: Ellen Goldberg, Miles D. Harrison, and Tiffany P. Olson.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation (say-on-pay).
Approval of non-employee director compensation policy.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and compensation policies.
Proxy holders have discretionary authority to vote on substitute nominees if any nominee is unable or unwilling to serve.
Latest events from Castle Biosciences
- Genomic testing enables precise SLNB decisions and improved melanoma outcomes.CSTL
Status update29 Apr 2026 - 2025 saw record revenue, strong governance, and enhanced compensation and ESG policies.CSTL
Proxy filing8 Apr 2026 - 2025 revenue hit $344.2M with 37% core test growth and strong cash reserves.CSTL
Q4 202526 Feb 2026 - Rapid TissueCypher adoption and strong Q3 results drive raised guidance and future growth.CSTL
Stephens 26th Annual Investment Conference | NASH20243 Feb 2026 - Strong growth in diagnostic testing, with expanding portfolio and positive reimbursement momentum.CSTL
Baird Global Healthcare Conference 20253 Feb 2026 - Q2 revenue up 74% to $87M; 2024 guidance raised amid strong growth and robust cash position.CSTL
Q2 20242 Feb 2026 - Expanding test adoption and sales force, with strong growth and plans to double melanoma penetration.CSTL
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q2 revenue and test volumes surged, with key diagnostics set for expanded market reach.CSTL
Baird's 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue up 39% to $85.8M, net income $2.3M, guidance raised to $320–330M.CSTL
Q3 202417 Jan 2026